Hypoxia is associated with an increase in systemic and cerebral formation of free radicals and associated reactants that may be linked to impaired cerebral vascular function and neurological sequelae. To what extent oral antioxidant prophylaxis impacts cerebrovascular function in humans throughout the course of acclimatization to the hypoxia of terrestrial high altitude has not been examined. Thus, the purpose of the present study was to examine the influence of orally ingested antioxidants at clinically relevant doses (vitamins C and E and -lipoic acid) on cerebrovascular regulation at sea level (344 m; n = 12; female n = 2 participants) and at high altitude (5050 m; n = 9; female n = 2) in a randomized, placebo-controlled and double-blinded crossover design.
INTRODUCTION
Oxidative stress refers to the imbalance between the production of pro-oxidants (e.g. free radicals) and available antioxidants (e.g. vitamin C). The physiological effect of oxidative stress is determined by the magnitude of this imbalance; homeostasis consists of low levels of oxidative stress (Trinity, Broxterman, & Richardson, 2016) , whereas high levels (albeit not yet precisely defined concentrations) are pathological and have been implicated in the structural damage and vascular dysfunction observed in multiple disease states (Ives et al., c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society 2014; Lavi, Gaitini, Milloul, & Jacob, 2006; Rossman et al., 2015; Ting et al., 1996) . Elevated markers of oxidative stress are evident in both acute (Irarrázaval et al., 2017) and chronic hypoxia , which may lead to a reduction in nitric oxide (NO) bioavailability through the interaction of NO and superoxide (i.e. free radical [O 2 − ]) to form peryoxynitrite (O 2 − + NO = ONOO − ; Meli, Nauser, Latal, & Koppenol, 2002; Thomas, Witting, & Drummond, 2008) . This reduction in NO bioavailability may ultimately decrease peripheral vascular function (Green, Jones, Thijssen, Cable, & Atkinson, 2011) (Smith et al., 1997) and hypoxic reactivity (Bailey et al., 2009a) .
Thus, as administration of antioxidants reduces overall total oxidative stress concentrations (Richardson et al., 2007) , this might improve cerebrovascular function. Excessive increases in oxidative stress have been observed in clinical populations with impaired cerebrovascular reactivity to CO 2 , such as diabetes (Lavi et al., 2006; Ting et al., 1996) and acute ischaemic stroke (Kotur-Stevuljevic et al., 2015; Reinhard et al., 2004) .
Although animal studies have demonstrated no effect of elevated oxidative stress on cerebrovascular CO 2 reactivity (e.g. experimental increases in the hydroxyl radical; Leffler et al., 1991; Rosenblum, 1983) , the limited studies conducted to date in humans indicate that oxidative stress may in fact impair cerebral reactivity (Hartmann et al., 2015; Hartmann, Pialoux, Leigh, & Poulin, 2012) . Nevertheless, the paucity of data in humans (especially healthy humans) is surprising given the susceptibility of the brain to changes in the redox balance. (Hartmann et al., 2015) . Given the recent criticisms of this assumption (reviewed by , further assessment of the role of antioxidants in cerebrovascular regulation is warranted where both diameter and velocity are both assessed.
Using a previously validated antioxidant cocktail (Richardson et al., 2007; Wray et al., 2012) combined with high-resolution duplex ultrasonography, in two separate studies, we investigated whether oral administration of antioxidants alters cerebral haemodynamics: (i) during acute exposure to hypercapnia and normobaric hypoxia; and (ii) after a 9 day trekking ascent and subsequent 12 days at high altitude (5050 m). Both studies used a double-blinded, randomized, placebocontrolled design at sea level (study 1) and high altitude (study 2).
In study 1, we hypothesized that the cerebral vascular response to hypercapnia and hypoxia would be reduced after the administration of oral antioxidants in young healthy subjects at sea level. In study 2, we anticipated that global cerebral blood flow (gCBF) would be increased after the administration of oral antioxidants in young healthy subjects at high altitude. 
METHODS

Ethical approval
Study 1: Sea-level testing (344 m)
Participants
Twelve healthy young individuals (24 ± 3 years of age; two females; body mass index 24 ± 2 kg m −2 ) volunteered to participate in study 1. Participants were screened to ensure reliable ultrasound measurements of the internal carotid artery (ICA). All participants were non-smokers, free of any cardiovascular, respiratory and cerebrovascular diseases, were non-diabetic and were not taking any prescription drugs (other than oral contraceptives n = 2) at the time of or before participation. A dietary food restriction sheet was given to all participants so that they could avoid foods high in antioxidants and nitrates (Kapil, Weitzberg, Lundberg, & Ahluwalia, 2014) .
Protocol design
Figure 1 illustrates the protocol design for studies 1 and 2. Study 1 required two separate laboratory visits that were separated by ≥48 h to account for adequate antioxidant washout (Bailey & Davies, 2001; Richardson et al., 2007) . Participants arrived at the laboratory having abstained from caffeine for 12 and from exercise and alcohol for 24 h, and had fasted for 4 h after a light meal. Upon arrival, participants were asked to lie in the supine position for 15 min while they were instrumented (see section 2.4 'Experimental measures' below).
After the 15 min rest period, baseline ventilatory, cardiovascular and cerebrovascular data were recorded during 5 min of room air breathing. Participants then breathed on an end-tidal forcing system (see section 2.4 'Experimental measures' below), where their room air partial pressures of end-tidal oxygen and carbon dioxide (P ET,O 2 and P ET,CO 2 , respectively; e.g. P ET,O 2 = 91.1 ± 13.0 mmHg and P ET,CO 2 = 42.4 ± 2.3 mmHg) were held constant for 2 min.
After the 2 min room air baseline period, the participants underwent 5 min of iso-oxic hypercapnia (+9 mmHg P ET,CO 2 ). Cerebral blood flow (CBF) and cerebral blood velocity of the ICA and MCA, For hypercapnia, the end-tidal CO 2 (P ET,CO 2 ) was increased 9 mmHg above baseline resting values. For hypoxia, the end-tidal O 2 (P ET,O 2 ) was decreased to 45 mmHg (to simulate arterial P O 2 at precisely 5000 m). Resting cardiovascular measurements were made of peripheral capillary saturation of oxygen, P ET,CO 2 , heart rate and mean arterial pressure. Resting CBF indicates resting cerebrovascular measurements from the internal carotid artery and vertebral artery respectively, were recorded during baseline and the last minute of hypercapnia. A 5 min recovery period followed the hypercapnic stage, before a second baseline was recorded for 2 min, followed by 10 min of isocapnic hypoxia (P ET,O 2 = 45 mmHg) with the P ET,O 2 targeted to mimic the P ET,O 2 at 5000 m based on a previous investigation by our group . Ultrasound images were recorded throughout the 2 min baseline and the 10 min trial, with the final 1 min used for analysis. After all measurements and recordings were completed, the participant ingested either a placebo (appearanceand weight-matched sugar pills) or antioxidant dose of vitamin C (500 mg), vitamin E (400 IU) and -lipoic acid (300 mg). A second dose (antioxidant or placebo) containing vitamin C (500 mg), vitamin E (200 IU) and -lipoic acid (300 mg) was ingested ∼30 min after the first antioxidant dose. For studies 1 and 2, antioxidant and placebo days were blinded to both the participants and investigators; this was initialized during each protocol. All data were unblinded after statistical analysis. The use of this specific oral antioxidant dose has been established previously to result in increased antioxidant concentrations within the blood and decreased systemic free radicalmediated lipid peroxidation (Richardson et al., 2007; Wray et al., 2012) .
Post-drug/placebo experimentation resumed exactly 60 min after the second dose of either placebo or antioxidants (Bailey & Davies, 2001; Richardson et al., 2007) .
Study 2: High-altitude testing (5050 m)
Participants
Nine healthy young individuals (24 ± 4 years of age; two females; body mass index 23 ± 2 kg m −2 ) volunteered for study 2. All participants were born and lived close to sea level (<1500 m). None of the participants had travelled to altitude (>1500 m) within ≥6 months before testing. Participants were screened to ensure reliable ultrasound measurements of the ICA. All participants were nonsmokers, free of any cardiovascular, respiratory and cerebrovascular diseases, were non-diabetic and were not taking any prescription drugs or antioxidant supplements (other than oral contraceptives n = 1, and intrauterine device n = 1) at the time of or before participation. In contrast to study 1, apart from the normal period of fasting (4 h), dietary restrictions were not enforced at high altitude, owing to the lack of control over the food options that were available to participants during the ascent and stay at the Pyramid research centre. However, the available foods did not have a high nitrate content (e.g. rice, lentils and potatoes). None of the participants experienced any symptoms of altitude illness at the time of testing.
High-altitude protocol design (Figure 1)
Similar to study 1, the design was double blinded, randomized and placebo controlled. Each laboratory visit was separated by 48 h to ensure adequate antioxidant washout (Richardson et al., 2007) While at the Pyramid laboratory, participants took part in several studies that were conducted throughout the 3 week period, but careful consideration of washout times and recovery meant that there was no crossover between studies. Moreover, the a priori primary research questions addressed in the present paper are novel and are exclusively dealt with in this study alone.
Participants were examined after refraining from caffeine for 12 h and from exercise and alcohol for 24 h, and were fasted for at least 4 h. Participants were instrumented and cardiorespiratory measures taken at the start of both the pre-and post-testing trials. Participants were requested to lie quietly in the supine position for 15 min upon arrival to allow for haemodynamics (i.e. heart rate, blood pressure and blood volume distribution) to reach baseline levels. After the collection of the cardiorespiratory variables detailed below, 2 min ultrasound recordings of both the ICA and vertebral artery (VA) were obtained.
Immediately after these CBF measures, similar to study 1, participants ingested two doses of either placebo or antioxidants (vitamins C and E and -lipoic acid).
Experimental measures 2.4.1 Study 1: Sea level
All cardiorespiratory variables were sampled continuously throughout the protocol at 1 kHz via an analog-to-digital converter (Powerlab, 16/30; ADInstruments, Colorado Springs, CO, USA). Heart rate (HR) was measured by a three-lead ECG (ADI bioamp ML132;
ADInstruments), and beat-to-beat blood pressure by finger photo- P ET,CO 2 and P ET,O 2 were sampled at the mouth, and recorded by a calibrated gas analyser (model ML206; ADInstruments). Ventilation (V E ), tidal volume and breathing frequency were measured by a pneumotachograph (model HR 800L; HansRudolph, Shawnee, KS, USA) connected in series to a bacteriological filter. Peripheral oxyhaemoglobin saturation (S pO 2 ) was measured using a pulse oximeter. All data measurements were displayed on LabChart (version 7.1; ADInstruments) and analysed offline. Analysis and collection of all data were performed blinded to the condition (i.e. placebo versus antioxidants).
Blood velocity and vessel diameter of the ICA were measured using 10 MHz multifrequency duplex ultrasound (Terason T3200; Teratech, Burlington, MA, USA). Arterial diameter was assessed with B-mode imaging, whereas pulse-wave mode was used simultaneously to measure peak blood velocity. Measures of ICA blood flow (Q ICA ) were made ipsilateral to MCA. Blood vessel diameter and blood velocity in the ICA were measured ≥1.5 cm distal from the common carotid bifurcation to eliminate measures of turbulent and retrograde flow. Blood velocity through the right MCA (MCAv) was measured using 2 MHz TCD (Spencer Technologies, Seattle, WA, USA). The TCD probes were secured in place using a specialized headband (model M600 bilateral head frame; Spencer technologies, Redmond, WA, USA) using standardized techniques (described by Willie et al., 2011 ).
In study 1, both P ET,CO 2 and P ET,O 2 were controlled using a dynamic end-tidal forcing system. The system uses independent gas solenoid valves for O 2 , CO 2 and nitrogen (N 2 ) and controls the volume of each gas delivered into a reservoir through a mixing and humidification chamber. The P ET,O 2 , P ET,CO 2 , expiratory and inspiratory tidal volumes, frequency of breathing and minute ventilation were determined for each participant on a breath-by-breath basis in real time using customdesigned software (Labview 13.0; National Instruments, Austin, TX, USA). The operation and use of our dynamic end-tidal forcing system has been described in detail previously Tymko, Ainslie, MacLeod, Willie, & Foster, 2015) . Cerebral reactivity to hypercapnia was calculated using the baseline CBF measure, subtracting the final minute of CBF measures during hypercapnia, then dividing by the overall change in P ET,CO 2 . Likewise, the following formula was used for the calculation of hypoxic reactivity: %∆CBF/−%∆S pO 2 .
Study 2: High altitude
Systolic, diastolic and MAP were recorded along with HR from an automated blood pressure cuff (HEM-775CAN; Omron Healthcare, Bannockburn, IL, USA). Respiratory rate and P ET,CO 2 were measured from a portable device (EMMA; Mainstream Capnometer, Danderyd, Sweden), and S pO 2 from a finger pulse oximeter (Vacu-med, Ventura, CA, USA).
In study 2, ICA flow was assessed as described in study 1. In addition, the diameter and velocity of blood in the vertebral artery (VA) were also measured between C4 and C5, between C5 and C6, or proximal to entry into the vertebral column. These locations were determined on an individual basis, with the same location repeated in each participant to acquire reproducible measures. The TCD was not used to assess MCAv in the high-altitude protocol.
At high altitude and at sea level, volumetric blood flow was calculated using the following formula:
For the high-altitude study, gCBF was calculated using the following formula:
Cerebrovascular conductance (CVC) was determined to account for differences in MAP during analysis of CBF responses. The CVC provides insight into the impact of MAP on CBF (CVC = CBF/MAP; Bailey et al., 2013a) . This was calculated for both ICA and VA (e.g.Q ICA /MAP andQ VA /MAP). Screen capture software was used for ultrasound recordings, and video files were stored for offline analysis. Analysis videos of both the ICA and VA were recorded and analysed while blinded to the protocol (placebo versus antioxidant). Edge-detection and wall-tracking software were used to determine measures of vessel diameter and peak blood velocity, and ≥12 consecutive cardiac cycle were used to determineQ ICA andQ VA (Woodman et al., 2001 ). For both studies, when interaction effects were detected pairwise comparisons were made using Bonferroni-corrected t tests.
Data analysis
RESULTS
Study 1: Acute hypercapnia and hypoxia
Cardiovascular and cerebrovascular baseline variables for placebo and antioxidants with iso-oxic hypercapnia (+9 mmHg P ET,CO 2 ) and isocapnic hypoxia (45 mmHg P ET,O 2 ) are presented in Tables 1 and 2, respectively. Both hypercapnia and hypoxia elevated MAP, HR andV E (P < 0.05 for both trials). During the hypercapnic trials, P ET,O 2 was maintained at each participant's baseline levels (P ET,O 2 = 92.5 versus 93.2 mmHg; P = 0.77) for each testing trial. Likewise, during the hypoxic trials P ET,CO 2 was maintained at each participant's baseline levels (P ET,CO 2 = 43.0 versus 42.7 mmHg; P = 0.67) for each testing trial.
There were no significant differences in the magnitude of end-tidal gas manipulations between placebo and antioxidants. Hypercapnia increasedQ ICA (P < 0.0001), ICAv (P = 0.01), ICA diameter (P = 0.001),
ICA CVC (P < 0.0001), and MCAv (P < 0.001). Likewise,Q ICA (P = 0.01), ICAv (P = 0.01), ICA diameter (P = 0.001), ICA CVC (P = 0.029) and MCAv (P = 0.001) all increased during isocapnic hypoxia. There were no between-trial (i.e. placebo versus antioxidant) differences for any cerebrovascular variables. Figure 2 shows individual data of both hypoxic and hypercapnic reactivity within the ICA preand post-intervention for placebo and antioxidants. As presented in 
Study 2: Chronic hypoxia
Cardiovascular and cerebral vascular variables are presented in Table 4 . There were no significant differences in MAP or S pO 2 pre- 
DISCUSSION
This is the first study to investigate whether antioxidant administration alters cerebrovascular regulation and blood flow in response to hypercapnia, acute hypoxia and chronic hypoxia in healthy humans. The primary findings from our study were that the administration of oral antioxidants did not alter (i) hypercapnic or hypoxic cerebrovascular reactivity at sea level (344 m) or (ii) gCBF at high altitude (5050 m).
Collectively, these findings highlight that at both sea level and high altitude, acute antioxidant administration does not alter cerebral vascular function in young healthy humans.
Cerebrovascular function, reactive oxygen species and antioxidants
We found no significant change in either MCAv or ICA flow reactivity to hypoxia at sea level. A previous study performed by Hartmann et al. (2015) reported a decrease in MCAv reactivity to isocapnic hypoxia in young healthy participants after I.V. infusion of vitamin C (3 g; Hartmann et al., 2015) . Differences between the findings of Hartmann et al. (2015) and the present study may be explained by their use of TCD to obtain velocity and not flow, because recent evidence has suggested that the MCA dilates in hypoxia (Verbree et al., 2014) , and that using only MCAv would ultimately underestimate CBF . In the present study, we observed dilatation within the ICA during both hypercapnia and acute hypoxia trials. Although the physical properties (i.e. anatomical size and compliance) differ
TA B L E 1
Cerebral vascular, haemodynamic and respiratory variables at baseline and during iso-oxic hypercapnia after placebo or antioxidants Table 1 .
TA B L E 3 Hypercapnic and hypoxic reactivity of the internal carotid artery after placebo or antioxidants
Placebo Antioxidant Parameter Pre Post ∆ Pre Post ∆ ICA [ml (100 g) −1 min −1 mmHg] 5.8 ± 2.0 6.8 ± 2.1 −1.0 ± 1.7 5.7 ± 2.0 5.8 ± 1.9 −0.1 ± 2.0 P value Condition P = 0.25; Pre versus Post P = 0.34; interaction P = 0.33 95% CI 0.98, 95% CI −0.07 to 2.04 0.11, 95% CI −1.57 to 1.79
ICA (%∆CBF/%∆P ET,CO 2 ) 15.1 ± 4.5 16.9 ± 4.6 1.7 ± 4.9 15.1 ± 5.3 15.0 ± 4.3 −0.1 ± 5.0 P value Condition P = 0.40; Pre versus Post P = 0.52; interaction P = 0.45 95% CI 1.73, 95% CI −1.38 to 4.84 −0.08, 95% CI ±3.00
ICA (%∆CBF/−%∆S pO 2 ) 1 . 8 ± 0.6 1.6 ± 0.5 −0.3 ± 0.7 1.5 ± 0.7 1.2 ± 0.8 −0.3 ± 0.5 P value Condition P = 0.46; Pre versus Post P = 0.12; interaction P = 0.96 95% CI −0.26, 95% CI −0.76 to 0.24 −0.27, 95% CI −0.62 to 0.08
All data are presented as means ± SD. Abbreviations: CBF, cerebral blood flow; Δ, change between pre and post within both placebo and antioxidant; ICA, internal carotid artery; and S pO 2 , peripheral capillary saturation of oxygen. There was no significant difference in all experimental trials at sea level (P = 0.96). (b) Relative CBF reactivity to hypercapnia in the internal carotid artery during all experimental trials at sea level. There was no significant difference in all hypercapnic experimental trials at sea level (P = 0.33) between intracranial and extracranial compartments, these data alone are consistent with previous reports of dilatation of the ICA as well as the MCA during changes in arterial blood gases Imray et al., 2014; Wilson et al., 2011) . Another consideration is that Hartmann et al. (2015) used a supraphysiological I.V. dose of vitamin C (3 g versus the upper recommended limit for daily intake of 2 g). This dose was speculated to have a pro-oxidant, instead of an antioxidant effect (Hartmann et al., 2015) . The dosing strategy used within the present study is likely to be more physiologically relevant.
Furthermore, the use of only a water-soluble antioxidant (i.e. vitamin C), as was done by Hartmann et al. (2015) , reduces aqueous superoxide and alkoxyl radicals (Bailey & Davies, 2001 ), but has a reduced ability to TA B L E 4 Cerebral vascular, haemodynamic and respiratory variables upon chronic exposure to high altitude after placebo or antioxidants ICAv (cm s −1 ) Pre 39.6 ± 7.1 39.7 ± 7.8 Condition P = 0.87; Pre versus Post P = 0.14; interaction P = 0.83 VA diameter (mm) Pre 6.2 ± 2.6 6.0 ± 2.5 Condition P = 0.96; Pre versus Post P = 0.54; interaction P = 0.11 Post 6.3 ± 2.5 6.9 ± 2.2 VA CVC (ml min −1 mmHg −1 ) Pre 4.0 ± 3.9 3.1 ± 3.0 Condition P = 0.82; Pre versus Post P = 0.78; interaction P = 0.32 Post 3.6 ± 3.3 4.0 ± 2.4 gCBF (ml min −1 ) Pre 895.6 ± 365.7 835.9 ± 332.7 Condition P = 0.65; Pre versus Post P = 0.97; interaction P = 0.43 Post 875.6 ± 379.5 944.1 ± 323.1
All data are presented as means ± SD for both between-trial placebo and antioxidant. Abbreviations: gCBF, global cerebral blood flow; ICA CVC, internal carotid artery cutaneous vascular conductance; ICA V , velocity of blood through the internal carotid artery; MAP, mean arterial pressure; P ET,CO 2 , end-tidal partial pressure of carbon dioxide;Q ICA , blood flow through the internal carotid artery;Q VA , blood flow through the vertebral artery; S pO 2 , peripheral capillary saturation of oxygen; VA CVC, vertebral artery cutaneous vascular conductance; and VA V , blood velocity through vertebral artery.
scavenge peroxyl radicals and related chain-breaking abilities (Regoli & Winston, 1999) . In contrast, lipid-soluble antioxidants target peroxyl radicals (Burton & Ingold, 1989) . Therefore, in the present study we used an antioxidant cocktail that contained water-soluble (e.g. vitamin C) and lipid-soluble (e.g. -tocopherol) chain-breaking antioxidants in combination with -lipoic acid, a unique 'ideal' antioxidant that is both water and lipid soluble (Packer, Roy, & Sen, 1997) . This dosing combination allows for greater oxidative stress scavenging and, as previously stated, this dosing has been proved to reduce oxidative stress levels within humans (Richardson et al., 2007) .
Similar to the hypoxia data, we found no significant change in either MCAv or ICA flow reactivity to hypercapnia at sea level after the administration of oral antioxidants. However, there may be an equal or greater influence of other redundant and compensatory mechanisms influencing vasomotor tone within the cerebral arteries during increased alterations of arterial CO 2 other than strictly NO-mediated signal transduction (Smith et al., 1997), such as prostaglandins, which upregulate cAMP, causing vasodilatation Pelligrino & Wang, 1998; St Lawrence et al., 2002) , cerebral autoregulation (Ogoh, Tzeng, Lucas, Galvin, & Ainslie, 2010) , and sympathetic activity (Peebles, Ball, MacRae, Horsman, & Tzeng, 2012) . In contrast, in chronic obstructive pulmonary disease patients, it was demonstrated using statistical covariate analysis that the elevated oxidative stress characteristic of these patients may underpin their impaired CO 2 reactivity when compared with control subjects (Hartmann et al., 2012) . However, in that study cerebral blood velocity was assessed only via TCD. Thus, the lack of experimental manipulation of oxidative stress and limited technique for CBF measurement make it difficult to draw strong inferences.
High altitude, cerebrovascular function and antioxidants
The present study is the first to assess gCBF after acclimatization Global cerebral blood flow (gCBF; the combination of both internal carotid artery and vertebral artery blood flow) in all experimental trials after chronic exposure to high altitude. There was no significant difference in all experimental trials at high altitude (P = 0.43) (Irarrázaval et al., 2017) and hypobaric hypoxia (Bailey et al., 2013b; Lewis et al., 2014) . Therefore, it is reasonable to hypothesize that this increase in oxidative stress might, in part, be responsible for the alternations in cerebral vascular function at high altitude (Jensen, Sperling, Severinghaus, & Lassen, 1996) . Within study 2, we reported the same consistent gCBF values that were previously reported after ∼1 week of acclimatization at the same altitude (e.g. 815 ± 50 ml min −1 ; Willie et al., 2014) . Resting CBF remained unchanged at altitude after the administration of acute oral antioxidants. As subjects were acclimatized and CBF had returned to sea-level values (650 ± 68 ml min −1 ) the antioxidant intervention might have had no effect because CBF was already 'normal' . Whether or not chronic antioxidant supplementation throughout the overall ascent or an increased dose might have resulted in different results remains to be established.
Methodological considerations
Large quantities of peroxidizable polyunsaturated fatty acid sidechains and a limited antioxidant defense leave the brain highly susceptible to high levels of oxidative stress (Bailey et al., 2009b) .
Furthermore, there are high concentrations of iron stores (McCord & Day, 1978) , in which interactions with oxidative stress might potentially lead to lipid peroxidation (Gutteridge, Halliwell, Treffry, Harrison, & Blake, 1983) . Collectively, these mechanisms may leave the brain more susceptible to oxidative stress and consequent dysfunction.
Thus, it is somewhat surprising that antioxidants had no effect;
however, this dosage has been demonstrated to reduce oxidative stress in peripheral venous blood samples, which might not be fully reflective of the cerebral vascular environment (Richardson et al., 2007) .
In the present study, we were able to examine the effects of oral antioxidant supplementation on cerebrovascular regulation at both sea level and high altitude. A double-blinded, placebocontrolled experimental design was implemented to account for any between-day variability, unlike previous studies. There are, however, a number of limitations related to our altitude study that we must acknowledge. First, with any high-altitude field study comes a number of potential confounders (e.g. altitude illness, increased sympathetic nervous activity and subject physical conditions). Second,
although the measures applied in study 1 provide greater insight into cerebrovascular regulation, we were not able to replicate the design owing to logistical issues associated with high-altitude field research and only quantified resting gCBF at high altitude. Third, we were able to recruit only a relatively small sample size at altitude (n = 9). Lastly, this study did not measure blood samples to track changes in oxidative stress both at sea level and at high altitude;
however, we chose an identical dosing strategy previously shown to increase antioxidant levels and reduce oxidative stress (Richardson et al., 2007) . We acknowledge, however, that the efficacy of this specific antioxidant cocktail has not been measured at terrestrial altitude. Travelling to terrestrial altitude may cause changes in both physical and psychological states and have an influence on drug absorption, distribution, metabolism and elimination given the impact on regional blood flow distribution (Donegani et al., 2016) . This influence may alter overall pharmacokinetic-pharmacodynamic properties of the administered drugs and might necessitate adjustments in dosage (Donegani et al., 2016; Peng & Cheung, 2011) .
Future considerations would be to assess CBF at multiple time points throughout the ascent and acclimatization to high altitude, perhaps with a more powerful antioxidant cocktail. Also, the use of cerebrovascular reactivity might provide a better overall assessment of cerebrovascular function at high altitude.
Conclusion
In conclusion, these data show that the use of an orally administered antioxidant cocktail known to attenuate systemic oxidative stress failed to alter cerebrovascular function of the ICA at sea level or gCBF after ascent and during acclimatization to high altitude, respectively.
